Introduction
Breast cancer is the most common malignancy diagnosed in women. A number of 231,840 new cases of breast cancer was expected in 2015, and 40,290 women were estimated to die from breast cancer in 2015 1 . In 2012 in Central Serbia, 3,186 new cases of breast cancer in women were registered and 1,175 cause-related deaths 2, 3 . There is an increasing incidence and mortality of breast cancer in Vojvodina, a northern part of Serbia (Figure 1) 3 . Positron emission tomography (PET) is a modern imaging method which plays an important role in oncology. 18 Ffluorodeoxyglucose ( 18 F-FDG) is a radiolabelled glucose analogue presenting a glucose metabolism marker. Since glucose uptake is increased in malignant tumors, 18 F-FDG PET has a major performance in oncology. A quantitative measurement of FDG uptake is expressed by the standardized uptake value (SUV) and is used mostly for diagnosis and response to treatment assessment. In fact, the SUV represents a relative measure of FDG uptake in tissue and is automatically calculated by PET and PET/computed tomography (CT) scanners as follows: SUV= r/(a/w), where r is the radioactivity measured within the region of interest (ROI) in kilobecquerels per millimeter (kBq/mm), a is the decay-corrected amount of injected radiolabeled FDG (kBq), and w is the weight of the patient (g). There are several factors that affect the SUV, such as plasma glucose concentration, the amount of injected FDG, the patient size and, the time from injection to imaging which is perhaps one of the most important factor 4, 5 . 18 F-FDG PET imaging is a so-called metabolic imaging because of the ability to detect malignant metabolism changes. These changes in fact, precede morphologic changes which are visualized by conventional anatomic imaging such as CT and magnetic resonance (MR).
In the last decade, PET and combined PET/CT were introduced in imaging of breast cancer. The CT part provides exact anatomic information and is used for attenuation correction of PET images. Comparing these two imaging modalities, PET/CT has been accepted to have better diagnostic accuracy than PET itself 6−8 . It has been reported that FDG uptake strongly correlates with high tumor proliferation index (Ki67 expression measured by immunohistochemical analysis) 9, 13, 14, 16 and p53 factor status 9, 12 . The relation between 18 F-DG uptake and steroid hormone receptor status is still controversial. Some authors reported no correlation between hormone receptor status and SUV values [11] [12] [13] 16 . Several studies detected a higher SUV in estrogen receptor negative (ER−) than in estrogen receptor positive (ER+) tumors 9, 17−19 . In contrast to Osborne et al. 19 who detected no correlation between the SUV and progesterone receptor status, Groheux et al. 20 documented a significant difference in 18 F-FDG uptake in progesterone receptor negative (PR−) tumors vs progesterone receptor positive (PR+) tumors (p = 0.003). Triple-negative breast tumors (negative for estrogen and progesterone receptors, and no human epidermal growth factor receptor-HER 2/neu overexpression) present a great subject to investigate because of their aggressiveness, poor prognosis and lack of targeted regimens. They are characterized with significantly higher SUV values than non-triple negative tumors 21 .
Indications

Primary tumor
18 F-FDG PET or 18 F-FDG PET/CT plays an important role in the diagnostic workup of breast cancer. However, it has no role in breast cancer screening due to limited spatial resolution (disability to detect tumors less than 10 mm) and the low sensitivity in less FDG-avid low-grade breast tumors. In a comparison study, Kumar et al. 22 concluded that tumor size and tumor grade are independent factors associated with false negative results. The eight times higher chances of obtaining false negative results were detected in smaller (< 10 mm) tumors vs larger (>10 mm) tumors. Results from another study showed that breast carcinomas were identified with an overall sensitivity of 64 23 reported that 18 FDG PET was 88% sensitive and 80% specific for detection of primary breast cancer showing false negative results in 12% cases. In another PET study done by Danforth et al. 24 , the primary breast cancer was accurately imaged with 90% sensitivity in early staged breast cancer (stage I, II). Moreover, 18 FDG-PET is able to image locally advanced skin changes in locally advanced tumors (stage III, IV). In the same study, 18 FDG-PET sensitivity for detection of the primary tumor, skin, and axillary lymph node metastases was 96%, 77%, and 83%, respectively. However, in comparison to MR, 18 FDG-PET is less sensitive and accurate in the assessment of the primary tumor and screening for tumor multifocality (54% vs 77%, respectively) 25 .
With the aim to overcome the low spatial resolution of 18 FDG-PET, a high-resolution PET scanners dedicated to breast imaging, so-called "positron emission mammography (PEM)" has been recently introduced. There are several publications based on clinical performance of PEM. In comparison to conventional whole-body PET, PEM is favorable in detection of ductal carcinoma in situ and lesions ≤ 1.0 cm. The advantages of 18 FDG-PEM include: reduced attenuation, improved geometric sensitivity, higher spatial resolution, shorter acquisition time (4−10 min), easy feasibility, device mobility, gentle breast immobilization, possible PEM-guided biopsy. The limitation of the study includes imaging of posterior lesions and variable 18 FDG uptake in small tumors 26−30 . In a recent study done by Berg et al. 31 , the efficacy of PEM was compared to MR imaging. At the lesion-level, PEM was more specific than MR (79.9% vs 65.6%) which helps in avoiding unnecessary biopsies. However, in detection of additional malignant lesions MR imaging was more sensitive than PEM which results in better assessment of disease extent and less frequent mastectomy (53% vs 41%) 31 . As generally accepted, 18 FDG-PET has no clinical role in diagnostic algorithm of suspicious breast lesions. How-ever, if there is inconclusive or suspicious mammography, 18 FDG PET may be useful. If 18 FDG PET unexpectedly detects FDG avid breast foci, patient needs additional conventional imaging and biopsy 32 . 
Axillary staging
SUV -standardized uptake value.
The status of axillary lymph nodes remains one of the most important prognostic indicators in patients with breast cancer. Sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) are standard procedures that are used for axillary staging. If axillary metastases are identified on SLNB, ALND is necessary. However, patients with negative SNB results may avoid ALND 33 . Despite high diagnostic accuracy, both SLNB and ALND are invasive procedures associated with morbidity, including lymphedema. Therefore, a non-invasive 18 FDG-PET imaging has been introduced for axillary staging in breast cancer. It is a metabolic radionuclide imaging technique that detects higher glycolytic rate of cancer cells in comparison to normal cells. The axillary lymph node involvement is shown at 18 F-FDG PET/CT ( Figure 2 ). Veronesi et al. 34 compared SLNB and 18 FDG-PET imaging, in detection of occult axillary metastases. Sensitivity of 18 FDG-PET scan was low (37%). However, specificity and positive predictive values were high (96% and 88%, respectively). The high specificity of PET imaging indicates that patients with a PET-positive axilla should have an ALND without SLNB for axillary staging. On the contrary, poor sensitivity of PET scan suggests the need for SLNB in patients with a PET-negative axilla.
A recent meta-analysis reported about lower sensitivity and specificity of PET in comparison to SLNB. Analysis of 7 PET/CT studies on 862 patients showed the mean sensitivity and specificity of 56% and 96%, respectively. Across 19 PET studies on 1,729 patients the mean sensitivity was 66% and the mean specificity 93%. In terms of evaluation of axillary extension, 18 FDG-PET cannot replace SLNB 35 . In another study, Gil-Rendo et al. 36 reported about 84.5% sensitivity and 98.5% specificity of FDG-PET in detecting axillary involvement. Avril et al. 37 performed FDG PET in women with suspected breast cancer in preoperative staging. They reported the sensitivity of 79% and specificity of 96% for detection of axillary lymph node metastases. Sensitivity increased to 94% in patients with primary breast tumors sized more than 2 cm. Similarly, Danforth et al. 24 suggested that sensitivity of PET in detection of axillary metastases increases with the stage of the disease. He reported sensitivity of 43% for stage I/II and 83% in stage III/IV.
A review by Rosen et al. 30 , suggests that 18 FGD-PET has no clinical role in a routine axillary staging of early stage breast cancer. However, preoperative 18 FDG-PET may be worthwhile in locally advanced and inflammatory breast cancers. In a multicentric study, detection of axillary nodal metastases by 18 FDG-PET was evaluated in 360 patients with newly diagnosed invasive breast cancer. The reported sensitivity and specificity were 61% and 80%, respectively 38 .
Distant metastases
18 FDG-PET is also important for detection of occult distant metastases. In high stage breast cancer, Alberini et al. 39 discovered more distant lesions by PET/CT than by conventional diagnostic procedures (31% vs 10%). Some authors reported advantage of PET/CT over conventional staging and detecting metastatic involvement of internal mammary chain nodes in patients with stage II and stage III breast cancer 40, 41 . In a work by Carkaci et al. 42 , out of 41 studied patients with inflammatory breast cancer, 24% of mediastinal nodal metastases and 15% of liver metastases were correctly identified by PET/CT. Figure 3 shows a patient with breast cancer and liver metastasis.
In the evaluation of metastatic bone involvement, PET is complementary to bone scintigraphy which remains the standard imaging procedure 30 . PET is superior for the detection of osteolytic and mixed bone metastases, but often fails to demonstrate blastic lesions. In contrast, bone scintigraphy is better for depicting sclerotic (blastic) lesions 43 . In a comparison study of bone scintigraphy versus PET/CT, Nakai et al. 44 reported on different detection rate for blastic, mixed and lytic type of lesions (100% vs 56% ; 84% vs 95% ; and 70% vs 100%, respectively).
In terms of accurate detection of bone metastases, 18 F sodium fluoride PET seems to be better than bone scintigraphy and 18 F-FDG PET/CT 45 . 
Recurrent cancer and restaging
SUV -standardized uptake value.
Current diagnostic strategy for the detection of recurrent disease in patients with breast cancer includes physical examination and imaging tests such as mammography, ultrasonography (US), CT, MR and bone scintigraphy. These diagnostic tests are part of routine clinical monitoring during the course of breast cancer. In patients without clinical symptoms and with rising levels of tumors markers PET imaging alone or combined with CT (PET/CT) is useful in detection of recurrent disease. Additionally, in proven recurrent disease or in suspicious recurrence by using conventional imaging, PET/CT helps to distinguish between isolated and multiple metastatic disease.
In a recent study by Aukema et al. 46 , additional lesions not visible at conventional imaging were detected by PET/CT in 45% cases. Results of one meta-analysis indicated that MR and PET (including PET and PET/CT) had higher sensitivity than US or CT, which resulted in higher detection rate of recurrent breast cancer. However, there was no difference in sensitivity between PET and MR 47 . Accross 28 studies included in the review Pennant et al. 48 found that PET had a significantly higher sensitivity (89% vs 79%) and significantly higher specificity (93% vs 83%) compared with conventional imaging tests. In addition, PET/CT had a significantly higher sensitivity compared with CT (95% vs 80%) but without a significant increase in specificity (89% vs 77%). Furthermore, PET/CT had a significantly higher sensitivity compared with PET (96% vs 85%) but no significant increase in specificity (89% vs 82%). There were no significant differences in the sensitivity or specificity of PET versus MRI, and PET/CT vs MRI, respectively.
In another study by Piperkova et al. 49 PET/CT and contrast enhanced CT were compared for initial staging in patients with breast cancer. They reported better diagnostic accuracy for PET/CT than contrast-enhanced CT (CE-CT): the sensitivity, specificity, accuracy, positive productive value, and negative productive value for PET/CT were 97.8%, 93.5%, 97.3%, 99.1%, and 85%, respectively, and for CE-CT were 87.6%, 42%, 82.1%, 91.6%, and 31.7%, respectively. The staging of the disease was changed in 65% of cases: 36% of patients were down-staged and 64% of patients were upstaged. PET imaging is important in restaging of breast cancer, because it might affect treatment management. An example of patient upstaging after 18 FDG PET/CT is shown in Figure 4 . In a study by Eubank et al. 50 PET revealed more lesions than CT and consequently altered therapeutic manage- ment in up to 44% of patients with suspected locoregional recurrent disease. 18 F-FDG PET/CT may have a potential role in clinically asymptomatic patients with rising markers and negative conventional imaging (US, X-mammography, CT and MR). Radan et al. 51 reported about 90% sensitivity of 18 FDG-PET in detection of recurrent disease. Consequently, treatment management was changed in 51% of patients. Additionally, if compared to contrast-enhanced CT, PET/CT showed better sensitivity (85% vs 70%), specificity (76% vs 47%), and accuracy (81% vs 59%). Similar results were obtained in a recent study by Dirisamer et al. 52 . They studied 52 patients and detected suspicious recurrence and rising tumor markers levels in 62%. PET/CT had better patient-based accuracy than CE-CT (96% vs 73%, respectively), and lesion-based sensitivity and specificity (93% vs 66% and 100% vs 92%, respectively). Grasseto et al. 53 studied patients with post-treatment rising tumor serum levels of Ca 15−3 but negative clinical examination and conventional imaging. 18 F-FDG PET/CT was able to detect cancer lesions in 45% of cases. Finally, there are reports that 18 F-FDG PET/CT imaging in patients with rising CA15-3 levels alters treatment management in up to 50% 54−56 .
Monitoring of the treatment response
Neoadjuvant or so-called preoperative chemotherapy is the initial standard treatment for patients with locally advanced breast cancer. This treatment results in a reduction of the tumor volume and is followed by conservative surgery and radiotherapy. The assessment of treatment response includes conventional methods such as physical examination, radiography, ultrasound and mammography. However, these methods are usually evaluated after completion of three cycles of chemotherapy. In addition, clinical response does not necessarily reflect the pathological response 57 . Due to the fact that changes in tumor metabolism precede the tumor shrinkage, 18 FDG PET is able to detect tumor response at an earlier stage than conventional imaging methods 58, 59 . Evaluation of changes in FDG uptake at different time points of the systemic treatment is based on comparison between the baseline (pretherapy) PET scan and postherapy PET scan. Some authors performed PET imaging early, after only 1 or 2 cycles, or during midtherapy, or at treatment completion. In the settings of early stage at chemotherapy, PET imaging is capable of predicting the pathologic response. In addition, PET is possible to distinguish between patients who respond to treatment (responders) and those who do not (non-responders) 30 . Approximately 70% of patients demonstrate clinical response to neoadjuvant chemotherapy, but only 20% achieve pathological complete response. Since the SUV decline early in the course of chemotherapy predicts a treatment failure, the regimen should altered with aim to avoid unnecessary toxic side effects 60, 61 . Jung et al. 62 suggested that the reduction rate of SUV has a prognostic value after the completion of the fourth cycle of chemotherapy before surgery. They detected 70% of sensitivity and specificity when 84.8% SUV reduction was used as a cutoff value for the pathologic complete response.
In another study, Schelling et al. 63 studied the role of 18 F-FDG PET in the assessment of early response to neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer. Decline in SUV values by more than 55% after one cycle, was predictive of a good response with sensitivity of 100% and specificity of 85%. In addition, after one and two cycles pathologic response was predicted with accuracy of 88% and 91%, respectively.
In nonmetastatic, non-inflammatory breast cancer, Kolesnikov-Gouthier et al. 64 detected < 15% of SUV decline after the first chemotherapy course which was used as a strong predictor for inefficient neoadjuvant chemotherapy. Additionally, a 4-year recurrence free survival rate was significantly longer in metabolic responders than nonresponders (85% vs 44%, respectively).
Park et al. 65 used diffusion weighted imaging (DWI) MR and PET/CT to predict pathologic complete response to preoperative neoadjuvant chemotherapy in patients with invasive breast cancer. PET/CT showed the same sensitivity of 100% as DWI MR, but better specificity (77.8% vs 70.4% ). A study by Andrade et al. 66 indicated that decrease of SUV values after the second course of neoadjuvant chemotherapy (NAC) can predict pathological response in ductal breast carcinomas, and potentially identify a subgroup of nonresponding patients. Keam et al. 67 analyzed the relation between changes in 18 FDG uptake and different molecular phenotype of breast cancer treated with neoadjuvant chemotherapy. During the early metabolic response, they detected that the estrogen receptor negative phenotype showed a higher pre-chemotherapy SUV (8.6 vs 6.4) and reduction rate of SUV (48% vs 30%) than estrogen receptor positive phenotype. In triple negative breast cancer, the prechemotherapy SUV was higher than in not triple-negative breast cancer (9.8% vs 6.4%).
In another study, Rousseau et al. 68 demonstrated the efficacy of 18 F-FDG PET in the assessment of early response to neoadjuvant chemotherapy in I/II staged breast cancer. They also analyzed the variation of SUV values after the first, second, third and six chemotherapeutic cycles. After 1 cycle of chemotherapy, using a 60% decline in baseline SUV as their threshold for response, PET was 61% sensitive and 96% specific with 68% predictive negative value. After 2 cycles, PET showed better sensitivity, specificity and negative predictive value (89%, 95%, 85%, respectively). After 3 courses of chemotherapy, if compared to values obtained after the second cycle, lower sensitivity, specificity and negative predictive value of PET were detected (88%, 73%, 83%, respectively). These results may suggest possible prediction of final response to treatment.
However, if 18 F-FDG PET is performed after the completion of chemotherapy residual FDG uptake may predict residual disease. In contrast, the absence of FDG uptake does not exclude residual microscopic malignancy and may not indicate pathologic response 69, 70 . In patients with large residual disease, 18 F-FDG PET is complementary to MR to define the degree of residual mass 71 . Moreover, if 18 F-FDG PET is performed after the chemotherapy it has a prognostic value. Cachin et al. 72 showed that negative PET scan was an indicator for a significantly better survival than PET positive scan. Additionally, 18 F-FDG PET scan was the most powerful and independent predictor of survival. Patients with negative post-treatment 18 
New positron emission tomography/ computed tomography tracers in breast cancer imaging
FDG is specific for increased metabolism of glucose and 18 F-FDG-PET/CT is able to detect the presence of viable tumor tissue in the human body. However, the new agents that are able to target the cellular processes have been recently developed. These agents are still under investigation and are not available in the routine clinical practice. The recent development of radiolabeled-thymidine compounds allows measurement of the exact tumor proliferation. According to some authors, the 18 F-fluoro-thymidine PET ( 18 FLT-PET) imaging has a role in the assessment of therapeutic response and prediction of response to therapy 73−76 . Regarding recently published data, PET is also able to evaluate estrogen take of 18 F-FES can reliably detect ER-positive lesions, its low uptake seems to be a strong predictor for failure of antihormonal therapy 77−81 . Another important feature of malignant disease is hypoxia. Numerous studies have been done on malignant tumors, mostly head and neck and lung cancers, but less in breast cancer. The results of these studies indicate that tumor hypoxia is important prognostic factor that influences the response to therapy and overall survival. In addition, hypoxia increases the risk of invasion and metastasis, as well as the resistance to chemo-and radio-therapy. Hussain et al. 82 correlated the hypoxia-regulated carbonic anhydrase (CA) IX expression with the outcome in patients with invasive breast cancer. They indicated that CA IX expression is a predictor of poor survival which may subsequently lead to better patient selection for adjuvant treatment. Additionally, hypoxia-related gene expression may present a basis for novel targeted therapies. In head and neck cancers, [ FMISO-PET) is proven to be a promising agent for detection and localization of significant hypoxia, delineation for external radiation, and for selecting treatment strategy 83 . In another study, Rajendran et al. 84 compared 18 FDG-PET to the 18 FMISO-PET in different malignant tumors, including breast cancer. They found that despite the fact that hypoxia influences glucose metabolism, some highly metabolic tumors are not hypoxic. They suggested that different tracer uptake in examined tumors can be tumor type-specific. The future will bring the results of currently ongoing studies with new, 18 FDG-PET, PET tracers 18 FMISO-PET evaluating tumor angiogenesis, chemo resistance and metastatic potential of malignant tumors.
Conclusion
18 F-FDG PET/CT is new non-invasive whole-body imaging of breast cancer. In particular, it helps in staging of recurrent or metastatic cancer and in evaluating the treatment response in patients with locally advanced and metastatic disease. Besides evaluation of increased glucose metabolism by FDG-PET, recently developed radiotracers have the ability to assess receptor expression, tumor cell proliferation and tumor viability in patients with breast tumors. However, future molecular imaging studies are necessary for better understanding of tumor biology and behavior. This is directly connected with the development of new PET agents and their introduction in clinical practice.
